RESPONSE TO RUXOLITINIB IN PATIENTS WITH INTERMEDIATE-1, INTERMEDIATE-2 AND HIGH-RISK MYELOFIBROSIS: RESULTS OF THE UK ROBUST TRIAL

被引：0
|
作者：
Mead, A. [1 ]
Clark, R. [2 ]
Chacko, J. [3 ]
Knapper, S. [4 ]
Yin, J. [5 ]
Milojkovic, D. [6 ]
Farquharson, M. [7 ]
Ali, S. [8 ]
Garg, M. [9 ]
Andrews, C. [10 ]
Dawson, M. Ktiouet [10 ]
Harrison, C. [11 ]
机构：
[1] Univ Oxford, Weatherall Inst Mol Med, MRC, Oxford, England
[2] Royal Liverpool Univ Hosp, Dept Haematol, Liverpool, Merseyside, England
[3] Royal Bournemouth & Christchurch Hosp NHS Fdn Tru, Bournemouth, Dorset, England
[4] Cardiff Univ, Dept Haematol, Cardiff CF10 3AX, S Glam, Wales
[5] Manchester Royal Infirm, Dept Haematol, Manchester M13 9WL, Lancs, England
[6] Hammersmith Hosp, Imperial Coll Healthcare NHS Trust, London, England
[7] Western Gen Hosp, Dept Haematol, Edinburgh EH4 2XU, Midlothian, Scotland
[8] Hull & East Yorkshire Hosp NHS Trust, Kingston Upon Hull, N Humberside, England
[9] Leicester Royal Infirm, Leicester, Leics, England
[10] Novartis Pharmaceut UK, Frimley, Camberley, England
[11] Guys & St Thomas Natl Hlth Serv Fdn Trust, London, England
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P414
引用
收藏
页码：131 / 132
页数：2
相关论文
共 50 条
  • [1] Response To Ruxolitinib In Patients With Intermediate-1, Intermediate-2 and High-Risk Myelofibrosis: Interim Results Of The UK Robust Trial
    Harrison, Claire N.
    Clark, Richard E.
    Chacko, Joseph
    Knapper, Steven
    Yin, John
    Milojkovic, Dragana
    Farquharson, Mira
    Ali, Sabra
    Garg, Mamta K.
    Andrews, Christopher
    Csci, Cstat
    Graham, Susan M.
    Mead, Adam J.
    [J]. BLOOD, 2013, 122 (21)
  • [2] Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial
    Mead, Adam J.
    Milojkovic, Dragana
    Knapper, Steven
    Garg, Mamta
    Chacko, Joseph
    Farquharson, Mira
    Yin, John
    Ali, Sahra
    Clark, Richard E.
    Andrews, Chris
    Dawson, Meryem Ktiouet
    Harrison, Claire
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (01) : 29 - 39
  • [3] Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence
    Harrison, Claire N.
    Talpaz, Moshe
    Mead, Adam J.
    [J]. LEUKEMIA & LYMPHOMA, 2016, 57 (10) : 2259 - 2267
  • [4] HIGH MOLECULAR RISK MUTATIONS ARE ASSOCIATED WITH CLINICAL RESPONSE AND OUTCOME IN INTERMEDIATE-1 RISK MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB
    Palandri, F.
    Bartoletti, D.
    Bonifacio, M.
    Iurlo, A.
    Benevolo, G.
    Elli, E. M.
    Auteri, G.
    Beggiato, E.
    Tieghi, A.
    Crugnola, M.
    Bosi, C.
    Ottaviani, E.
    Caocci, G.
    Polverelli, N.
    Cavazzini, F.
    Tiribelli, M.
    Pugliese, N.
    Binotto, G.
    Isidori, A.
    Lemoli, R. M.
    Cilloni, D.
    Martino, B.
    Abruzzese, E.
    Bocchia, M.
    Latagliata, R.
    Cavo, M.
    Vianelli, N.
    Breccia, M.
    Palumbo, G. A.
    [J]. HAEMATOLOGICA, 2021, 106 (10) : 84 - 85
  • [5] Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study
    Palandri, Francesca
    Tiribelli, Mario
    Benevolo, Giulia
    Tieghi, Alessia
    Cavazzini, Francesco
    Breccia, Massimo
    Bergamaschi, Micaela
    Sgherza, Nicola
    Polverelli, Nicola
    Crugnola, Monica
    Isidori, Alessandro
    Binotto, Gianni
    Heidel, Florian H.
    Buccisano, Francesco
    Martino, Bruno
    Latagliata, Roberto
    Spinsanti, Marco
    Kallenberg, Lydia
    Palumbo, Giuseppe Alberto
    Abruzzese, Elisabetta
    Scaffidi, Luigi
    Cuneo, Antonio
    Cavo, Michele
    Vianelli, Nicola
    Bonifacio, Massimiliano
    [J]. HEMATOLOGICAL ONCOLOGY, 2018, 36 (01) : 285 - 290
  • [6] Promise: Investigation into the Combination of a Potent Beti with Ruxolitinib in Patients with High or Intermediate-2 Risk Myelofibrosis Not Receiving an Adequate Response with Ruxolitinib Alone
    Mead, Adam J.
    Harrison, Claire N.
    Huntly, Brian
    Psaila, Bethan
    Boucher, Rebecca
    Fox, Sonia
    Hopkins, Louise
    Rogers, Joseph
    Gaskell, Charlotte
    Patel, Amit
    [J]. BLOOD, 2023, 142
  • [7] Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis
    Pardanani, Animesh
    Tefferi, Ayalew
    Masszi, Tamas
    Mishchenko, Elena
    Drummond, Mark
    Jourdan, Eric
    Vannucchi, Alessandro
    Jurgutis, Mindaugas
    Ribrag, Vincent
    Rambaldi, Alessandro
    Koh, Liang Piu
    Rose, Shelonitda
    Zhang, Jun
    Harrison, Claire
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2021, 195 (02) : 244 - 248
  • [8] Burden of Disease and Clinical Responses in Low and Intermediate-1 Risk Myelofibrosis Patients Treated with Ruxolitinib
    Zarzour, Ahmad
    Tabarroki, Ali
    Visconte, Valeria
    Taftaf, Rokana
    Rogers, Heesun J.
    Ai, Jing
    Papadantonakis, Nikolaos
    Lichtin, Alan E.
    Saunthararajah, Yogen
    Stein, Brady L.
    Tiu, Ramon V.
    [J]. BLOOD, 2014, 124 (21)
  • [9] Fedratinib hydrochloride to treat intermediate-2 or high-risk primary or secondary myelofibrosis
    Schiffer, M.
    Kowalski, A.
    Zhao, J.
    Bewersdorf, J. P.
    Lewis, R. S., Jr.
    Zeidan, A. M.
    [J]. DRUGS OF TODAY, 2020, 56 (12) : 755 - 768
  • [10] A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2)
    Vianelli, Nicola
    Benevolo, Giulia
    Vannucchi, Alessandro
    Harrison, Claire N.
    Loschi, Michael
    Al-Ali, Haifa Kathrin
    Bonifacio, Massimiliano
    Cervantes, Francisco
    Wrobel, Tomasz
    Barosi, Giovanni
    Kiladjian, Jean-Jaques
    Verstovsek, Srdan
    Mesa, Ruben A.
    Rose, Shelonitda
    Gharpure, Vishwanath
    Hernandez, Christopher
    Zhang, Jun
    Passamonti, Francesco
    [J]. BLOOD, 2021, 138
12345